Efficacy and safety of thalidomide in patients with hepatocellular carcinoma

Table 1 Clinical characteristics of 42 patients with HCC

Characteristic	n	yr	%
Age
Median		67
Range		32-84
Sex
Male	11		26
Female	31		74
Comorbidity
Absent	10		24
Present	32		76
Cirrhosis
Absent	11		26
Present	31		74
Type of hepatitis
Hepatitis B	15		36
Hepatitis C	11		26
Hepatitis B + hepatitis C	1		2
Hepatitis B + hepatitis D	1		2
No record	14		33
TNM stage
I	2		5
II	6		14
IIIA	21		50
IIIB	2		5
IVA	7		17
IVB	4		10
Child-Pugh classification
Grade A	25		60
Grade B	14		33
Grade C	3		7
Okuda stage
I	11		26
II	27		64
III	4		10
CLIP score
0	2		5
1	10		24
2	7		17
3	15		36
4	4		10
5	4		10
6	0		0
α-fetoprotein
> 400 ng/mL	21		50
≤ 400 ng/mL	21		50
Pre thalidomide therapy
TAE1	26		62
PEI + TAE1	3		7
Radiation + TAE1	2		5
Surgery + PEI2	1		2
Chemotherapy	1		2
No therapy	9		21

¹Transarterial embolization;

²Percutaneous ethanol injection.